Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How will genomic testing impact a clinician's choice for managing chronic myeloid leukemia?

Expert review of hematology - 1 Oct 2025

Sia Jessica, Shanmuganathan Naranie

Abstract excerpt

INTRODUCTION: Chronic myeloid leukemia (CML) is a disease characterized by a single diagnostic molecular abnormality and epitomizes a genetically based diagnosis and management. Targeted therapy with tyrosine kinase inhibitors has revolutionized treatment and prognosis of this disease; however, a proportion of patients will experience resistance to therapy and progress to blast phase, the terminal phase of this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Decision-Making
Share to Disease Management
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Testing

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 40638099
DOI: 10.1080/17474086.2025.2533235

Genes

ASXL1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How will genomic testing impact a clinician's choice for managing chronic myeloid leukemia?PMID 40638099Read ↗

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.Semantic proximity Read ↗

Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia.Semantic proximity Read ↗

Genetic landscape of chronic myeloid leukemia.Semantic proximity Read ↗

Acute Myeloid Leukemia Genetics: Risk Stratification and Implications for Therapy.Semantic proximity Read ↗

Genomic Mechanisms Influencing Outcome in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and TreatmentSemantic proximity Read ↗

Genomics of Acute Myeloid Leukemia: The Next GenerationSemantic proximity Read ↗

Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.Semantic proximity Read ↗

How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?Semantic proximity Read ↗

Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic StrategiesSemantic proximity Read ↗

Beyond BCR::ABL1—The Role of Genomic Analyses in the Management of CMLSemantic proximity Read ↗

Genomic tools in acute myeloid leukemia: From the bench to the bedside.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.